The STATs of cancer — new molecular targets come of age

Yu, Hua; Jove, Richard

doi:10.1038/nrc1275

Cited by 2,278Cytokine Signaling Pathways and InteractionsProtein Tyrosine PhosphatasesCancer Mechanisms and Therapy

The STATs of cancer — new molecular targets come of age

Yu, Hua, Jove, Richard·2004·Nature Reviews Cancer

DOI 10.1038/nrc1275

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nrc1275

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The STAT3 protein is overexpressed and/or hyperactivated in the majority of human cancers.
“The STAT3 protein is overexpressed and/or hyperactivated in the majority of human cancers.37”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [37]
STAT3 is constitutively activated in human malignancies, in contrast to normal biology where transient STAT3 signaling is strictly regulated.
“STAT3 is constitutively activated in human malignancies.”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [37]
Inhibition of STAT3 upstream signaling alone is insufficient to overcome activation of compensatory signaling pathways.
“Furthermore, the inhibition of STAT3 upstream signaling alone is insufficient to overcome the activation of compensatory signaling pathways (12, 13).”
From Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer (2022) · cites this paper as [13]
Most reported STAT3 targeting modalities have significant drawbacks due to the absence of active sites or allosteric regulatory pockets.
“While there are several reported STAT3 targeting modalities, most of them have significant drawbacks due to the absence of active sites or allosteric regulatory pockets, and the landscape for promising STAT3 inhibitors remains murky (13).”
From Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer (2022) · cites this paper as [13]

Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works
Oncogenic kinase signalling.
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · see citing works
STATs in oncogenesis
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · see citing works
Self-citation
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · see citing works
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · see citing works
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · see citing works
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., & Jove, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131568898 · Cited by 488 · see citing works
Self-citation
STAT3 deletion during hematopoiesis causes Crohn’s disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity
Welte, T., Zhang, S. S. M., Wang, T., Zhang, Z., Hesslein, D. G. T., Yin, Z., Kano, A., Iwamoto, Y., Li, E., Craft, J. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237137100 · Cited by 381 · see citing works
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340 · see citing works

Flagged first, then by citations

Sorted by citations

Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · see citing works
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · see citing works
Self-citation
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · see citing works
A renaissance for SRC
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · see citing works
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010 · see citing works
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652 · see citing works
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · see citing works
Constitutive activation of <scp>STAT</scp>3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611 · see citing works
SOCS3, a Major Regulator of Infection and Inflammation
Carow, B., & Rottenberg, M. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00058 · Cited by 555 · see citing works
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · see citing works
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409 · see citing works
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322 · see citing works
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307 · see citing works
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233 · see citing works
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211 · see citing works
A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179 · see citing works
IFN Induces miR-21 through a Signal Transducer and Activator of Transcription 3–Dependent Pathway as a Suppressive Negative Feedback on IFN-Induced Apoptosis
Yang, C. H., Yue, J., Fan, M., & Pfeffer, L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2579 · Cited by 179 · see citing works
An integrative ENCODE resource for cancer genomics
Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14743-w · Cited by 172 · see citing works
Helicobacter pylori Cytotoxin-Associated Gene A Activates the Signal Transducer and Activator of Transcription 3 Pathway In vitro and In vivo
Bronte-Tinkew, D. M., Terebiznik, M., Franco, A., Ang, M., Ahn, D., Mimuro, H., Sasakawa, C., Ropeleski, M. J., Peek, R. M., & Jones, N. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1191 · Cited by 154 · see citing works
Optic nerve astrocyte reactivity protects function in experimental glaucoma and other nerve injuries
Sun, D., Moore, S., & Jakobs, T. C. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160412 · Cited by 130 · see citing works
Natural Withanolides in the Treatment of Chronic Diseases
White, P. T., Subramanian, C., Motiwala, H. F., & Cohen, M. S. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-41334-1_14 · Cited by 139 · see citing works
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Spitzner, M., Roesler, B., Bielfeld, C., Emons, G., Gaedcke, J., Wolff, H. A., Rave‐Fränk, M., Kramer, F., Beissbarth, T., Kitz, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28429 · Cited by 128 · see citing works
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities
Mottok, A., Renné, C., Seifert, M., Oppermann, E., Bechstein, W., Hansmann, M.-L., Küppers, R., & Bräuninger, A. (2009) · Blood · doi:10.1182/blood-2009-06-225839 · Cited by 124 · see citing works
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works
Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122 · see citing works
“IL-10 is frequently overly produced in tumors and is a key activator of signal transducer and activator of transcription 3 (Stat3), which is activated in numerous cancers, promoting expression of diverse molecules important for tumor cell proliferation, survival, invasion, and metastasis (7).”
Self-citation
The STAT3–IL-10–IL-6 Pathway Is a Novel Regulator of Macrophage Efferocytosis and Phenotypic Conversion in Sterile Liver Injury
Campana, L., Starkey Lewis, P. J., Pellicoro, A., Aucott, R. L., Man, J., O’Duibhir, E., Mok, S. E., Ferreira-Gonzalez, S., Livingstone, E., Greenhalgh, S. N., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701247 · Cited by 107 · see citing works
Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96 · see citing works
Role of epigenetics in transformation of inflammation into colorectal cancer
Yang, Z.-H., Dang, Y.-Q., & Ji, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2863 · Cited by 81 · see citing works
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition
Courapied, S., Sellier, H., de Carné Trécesson, S., Vigneron, A., Bernard, A.-C., Gamelin, E., Barré, B., & Coqueret, O. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.092304 · Cited by 76 · see citing works
STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression
Kim, K.-J., Kwon, S.-H., Yun, J.-H., Jeong, H.-S., Kim, H.-R., Lee, E. H., Ye, S.-K., & Cho, C.-H. (2017) · Oncogene · doi:10.1038/onc.2017.148 · Cited by 70 · see citing works
Selective STAT3-α or -β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes
Ng, I. H. W., Ng, D. C. H., Jans, D. A., & Bogoyevitch, M. A. (2012) · Biochemical Journal · doi:10.1042/bj20120941 · Cited by 63 · see citing works
DNA‐Binding Small Molecules as Inhibitors of Transcription Factors
Leung, C., Chan, D. S., Ma, V. P., & Ma, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21266 · Cited by 58 · see citing works
Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
Jin, J., Wu, Y., Zhao, Z., Wu, Y., Zhou, Y.-D., Liu, S., Sun, Q., Yang, G., Lin, J., Nagle, D. G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160606 · Cited by 57 · see citing works
“Furthermore, the inhibition of STAT3 upstream signaling alone is insufficient to overcome the activation of compensatory signaling pathways (12, 13).”
Critical analysis of the potential for targeting STAT3 in human malignancy
Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24 · see citing works
“Role of STAT3 in cancer Genomic and epigenomic deregulation of STAT3 in cancer The STAT3 protein is overexpressed and/or hyperactivated in the majority of human cancers.(37) The prevalence of STAT3 overactivation in cancer cannot be explained by mutational activation of STAT3 because somatic mutation”
Blockage of the JAK/STAT3 signaling pathway in multiple myeloma by leelamine
Jung, Y. Y., Um, J.-Y., Nasif, O., Alharbi, S. A., Sethi, G., & Ahn, K. S. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153574 · Cited by 19 · see citing works
Type I IFN receptor blockade alleviates liver fibrosis through macrophage-derived STAT3 signaling
Park, S.-J., Garcia Diaz, J., Comlekoglu, T., & Hahn, Y. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528382 · Cited by 10 · see citing works

Authors: Yu, H., & Jove, R.
Affiliations: University of South Florida (US)
ORCID: Yu, Hua
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2004-02
Volume: 4
Issue: 2
Pages: 97-105
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc1275
OpenAlex: W1548640328
Cited by: 2,278
References: 12
Citations by year: 2026: 31 · 2025: 47 · 2024: 62 · 2023: 92 · 2022: 70 · 2021: 101 · 2020: 95 · 2019: 110 · 2018: 102 · 2017: 112 · 2016: 109 · 2015: 128 · 2014: 152 · 2013: 149 · 2012: 144
FWCI: 9.07
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
U.S. National Library of Medicine
Topics: Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
Keywords: STAT proteins, STAT3, STAT5, cancer therapy targets, tumor cell proliferation, apoptosis resistance, angiogenesis, immune evasion, signal transduction
MeSH terms: Cell Division, DNA-Binding Proteins, Humans, Milk Proteins, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Trans-Activators, Apoptosis, STAT2 Transcription Factor, STAT5 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The STATs of cancer — new molecular targets come of age

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Record

About these checks